Perspectives

Epidemiology of Therapy-Related Myeloid Neoplasms After Treatment for Pediatric Acute Lymphoblastic Leukemia in the Nordic Countries.

Kjeld Schmiegelow

Faculty of Medicine, Institute of Gynecology, Obstetrics and Pediatrics, and the Department of Pediatrics, the University Hospital Rigshospitalet, Copenhagen, Denmark.

Correspondence to: Kjeld Schmiegelow, professor M.D., Dr.Med.Sci., The Department of Pediatrics, The Juliane Marie Center 5704, University Hospital Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. Telephone: +45 3545 1357, Fax: +45 3545 4524, E-mail: kschmiegelow@rh.dk

Competing interests: The authors have declared that no competing interests exist.

Published: May 16, 2011
Received: March 28, 2011
Accepted: May 3, 2011
Mediterr J Hematol Infect Dis 2011; 3: e2011020, DOI 10.4084/MJHID.2011.020
This article is available from: http://www.mjhid.org/article/view/8283
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract: Of 1614 Nordic children with ALL that were treated according to the NOPHO ALL92 protocol, 20 developed an SMN (cumulative risk at 12 years: 1.6%). Sixteen of the twenty SMNs were acute myeloid leukemias or myelodysplasias, and 9 of these had either monosomy 7 (n=7) or 7q deletions (n=2). In Cox multivariate analysis longer duration of oral MTX/6MP maintenance therapy (p=0.02; being longest for standard risk patients) and presence of high-hyperdiploidy (p=0.07) were related to an increased risk of SMN. In 524 patients we determined the erythrocyte levels of methylated metabolites that inhibit purine synthesis and thus reduces cellular levels of cytotoxic 6-thioguanine nucleotides. The TPMT activity was significantly lower in those that did compared to those that did not develop an SMN (Median: 12.1 vs 18.1 IU/ml; p=0.02). Among 427 TPMT wild type patients, those who developed SMN received higher 6MP doses than the remaining (69.7 vs 60.4 mg/m², p=0.03), which may reflect increased levels of methylated metabolites that inhibit purine de novo synthesis and thus enhance incorporation of 6-thioguanine nucleotides into DNA. In conclusion, the duration and intensity of 6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMN.

Introduction: One of the most devastating complications to the therapy of childhood acute lymphoblastic leukemia (ALL) is the development of second cancers (SMN), a complication that in general has a poor prognosis.1-5 Although on average it occurs in 2% of all patients depending on the therapy given, the published cumulative incidences vary from less than 1% to almost 10%.6-8 Furthermore, since the overall survival of childhood ALL now approaches 85%, SMN now encompass 15-20% of all deaths after childhood ALL therapy.

The incidence of SMN will be influenced not only by the treatment modalities applied but also by the duration of follow-up, since SMN may emerge several decades from the initial ALL treatment. Furthermore, some centres actively screen for subclinical cancers,
Pattern of SMN in NOPHO 81-2009

|                | Low-toxic therapy | >60% received Cranial RTx | Intensified maintenance | Similar to ALL92 |
|----------------|-------------------|---------------------------|-------------------------|------------------|
| N              | 8                 | 14                        | 21                      | 6                |

Figure 1: Pattern and incidence of second neoplasms (SMN) among Nordic patients treated during four consecutive Nordic protocol periods. Numbers at the top of columns are the total number of SMNs in that protocol period. CNS = central nervous system; RTx = radiotherapy; AML = acute myeloid leukemia; MDS = myelodysplasia.

e.g. meningiomas and thyroid cancers. Finally, the strategies or reporting of SMNs differ widely between collaborative groups ranging from no-news-are-good-news to follow-up by regular questionnaires or systematic exchange of data with national or regional cancer registries, which in the Nordic countries are population-based and enforced by legislation and by exchange of data with the National hospital discharge registration.

Treatment-related risk factor analyses have primarily focused on irradiation, alkylating agents, and topoisomerase II inhibitors (anthracyclines, epipodophyllotoxins) that induce DNA damage, whereas less attention has been paid to mechanisms that interfere with DNA control, including drugs that may modify DNA repair. Previously, children with higher risk ALL had the highest risk of SMN due to their more intensive chemotherapy and radiotherapy and the use of hematopoietic stem cell transplantation. However, studies from the Nordic Society for Paediatric Haematology and Oncology (NOPHO) and from St Jude Children’s Research Hospital have indicated that even the less intensive 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy may enhance the risk of SMN not least for patients with thiopurine methyltransferase (TPMT) low-activity polymorphisms. Since TPMT methylates 6MP and some of its metabolites and thus reduces the intracellular amounts of cytotoxic 6-thioguanine nucleotides (6TGN) available for DNA incorporation, the 5-10% of patients who have low TPMT activity will have higher intracellular 6TGN levels for DNA incorporation and DNA damage.

Based on these findings, the predominance of therapy-related acute myeloid leukemia and myelodysplasia (t-AML/MDS) in the two most recent Nordic ALL protocols (Figure 1), and since 75% of the SMNs occurred among standard risk patients, we analyzed in depth the occurrence of SMN in the NOPHO ALL92 by taking advantage of an extensive registration of individual data on maintenance therapy during the first years of the protocol.

Patients and Methods: Patients: From January 1992 until October 2001, 1614 children 1.0-14.9 years of age were diagnosed with B-cell precursor or T-cell ALL in the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) and were treated according to the NOPHO ALL92 protocol.8

Risk grouping: The risk group criteria are given in table 1.13 The patients who had higher risk features at diagnosis and were assigned to the very high risk
(VHR) treatment arm received prophylactic or therapeutic central nervous system (CNS) irradiation as well as LSA/L2 instead of MTX/6MP maintenance therapy.14

Induction therapy and consolidation therapy have previously been published in detail.13

CNS irradiation and stem cell transplantation: Due to CNS disease at diagnosis or allocation to the very high risk protocol arm 123 non-transplanted patients (7.6% of the total study population) received cranial irradiation in 1st remission (CR1). 31 boys and 21 girls with higher-risk criteria received a hematopoietic stem cell transplantation in CR1.15

Oral 6MP/MTX maintenance therapy was initiated at treatment week 13 (standard risk, SR), 32 (intermediate risk, IR), or 63 (high risk, HR) and scheduled to continue until 2 years (IR and HR) or 2½ years (SR) after diagnosis. Between 1992 and 1996, 538 patients with SR+, IR+, or HR-ALL were included in the randomised ALL-92 maintenance therapy trial. As part of that study we registered all data on MTX and 6MP doses as well as all blood counts (28.000 data sets in total), and furthermore added data on MTX and 6MP dosing and blood counts during maintenance therapy for the patients with SMN that were not included in the randomised study. The genotype (low activity polymorphisms G460A and A719G) and/or erythrocyte TPMT activity was available for 609 patients. Erythrocyte TPMT activity was measured during maintenance therapy and at least 8 weeks from the last red blood cell transfusion. For 484 of these patients only the erythrocyte TPMT activity was available. The antimode of the TPMT activity distribution was 14 IU/ml, and patients with TPMT activity below that level, and for whom no TPMT genotype was available, were classified as TPMT presumed heterozygous.

Results and Discussion: With a median follow-up of 10.4 years for patients who remain in first remission, a total of 20 patients developed an SMN at a median of 3.4 years from the diagnosis of ALL (risk at 12 years: 1.6%) (Table 1). The 12-year cumulative risk of developing an SMN (pSMN12) was 1.6 +/- 0.4%. The projected risk of SMN among the non-transplanted patients was significantly related to the risk group and was 2.4 +/- 0.7% for SR-ALL, 1.2 +/- 0.7% for IR-ALL, and 0.3 +/- 0.3% for higher risk ALL patients (p = 0.007) (Table 1). The cumulative risk of developing SMN was 1.7 +/- 0.4% for the 1316 patients who were in CR1 when they initiated MTX/6MP maintenance therapy vs 0% for the 169 patients in CR1 at the start of LSA/L2 maintenance therapy. Twelve of the 20 SMN patients died within 21 months from diagnosis of their SMN with a median time to death of 8.8 months and a projected survival of 39% +/- 11%.

Sixteen of the twenty SMNs were t-AML/MDS, and 9 of these had either monosomy 7 (n=7) or 7q deletions (n=2). Eight of the nine -7/-7q- t-AML/MDS cases occurred among patients with high-hyperdiploidy (n=4), t(12;21)(p13;q22) (n=1), or a normal/missing karyotype at diagnosis of ALL, which indicates a biological propensity for non-disjunction, although the results did not reach statistical significance. In Cox multivariate analysis, longer duration of oral MTX/6MP maintenance therapy (p = 0.02; being longest for standard risk patients) and presence of high-hyperdiploidy (p = 0.07) were related to increased risk of SMN. Among all 562 SR-ALL patients, the 161 patients with a high-hyperdiploid karyotype had a 4.8 +/- 1.8% risk of developing SMN compared to a 1.5 +/- 0.6% risk for the remaining 401 SR patients (p = 0.02).

The patients who developed an SMN had significantly lower TPMT activity than the remaining patients (Median: 12.1 vs 18.1 IU/ml; p = 0.02), and they received 10–15% higher 6MP doses than those that did not develop an SMN, and this was the case both among patients classified as TPMT low activity (Median: 55.5 (N=3) vs 50.3 mg/m² (N=57); p = 0.31) and those classified as TPMT wild type (Median: 69.7 (N=9) vs 60.4 mg/m² (N=418); p = 0.03). The positive relation between 6MP dosage and risk of SMN is likely to reflect that TPMT-mediated thiopurine methylthation, not least through 6-methyl-thioinosine 5'-monophosphate, will inhibit purine de novo synthesis, and since 6-methyl-thioinosine 5'-monophosphate levels preferentially increase with upward dose adjustments of 6MP, this may cause enhanced DNA-6TGN incorporation. Such a relationship is supported by the recent demonstration of a positive correlation between erythrocyte levels of methylated 6MP metabolites versus the index between DNA-6-thioguanine nucleotide levels in nucleated cells and the erythrocyte levels of 6-thioguanine nucleotides.

Several drugs have been suggested to modify the risk of SMN by promoting the growth of a malignant clone or by interference with DNA-repair. Such agents include granulocyte colony stimulating factor, L-asparaginase, and thiopurines. The present population-based, retrospective study strongly indicates that maintenance therapy, and especially 6MP pharmacotherapy, influenced the development of SMNs, since 6MP can cause DNA damage, and the risk of t-AML/MDS was related to i) longer duration of 6MP/MTX maintenance therapy, ii) low TPMT activity, and iii) significantly higher doses of 6MP for TPMT wild type patients. During oral 6MP therapy
Table 1. Risk group, therapy, and second malignant neoplasms in NOPHO ALL-92 protocol

| Risk criteria          | SR-ALL | IR-ALL | HR-ALL | VHR-ALL |
|------------------------|--------|--------|--------|---------|
| Age: 2.0-9.9 and WBC: <10x10^9/L, No HR/VHR-criteria | 562    | 590    | 239    | 223     |
| Age: 1.0-1.9 or ≥10.0 and/or WBC: 10-49 x10^9/L, No HR/VHR-criteria | 120    | 240    | 280    | 400     |
| Risk criteria          |        |        |        |         |
| WBC = 50x10^9/L, T-cell, mediastinal or CNS or testicular or lymphomatous disease, t(4;11) or (9;22), M3 d15 or M2/3 d29, no VHR-criteria | 3.000  | 3.000  | 6.600  |         |
| HR-ALL at diagnosis & age ≥5y & i) CNS leukemia, or ii) lymphomatous leukemia, or iii) d15 M3 or a d29 M2/3 BM, or iv) T-ALL with ≥1 other HR-features | Yes   |        |        |         |
| Patients               | 117    | 72     | 41     | 0-8     |
| Doxorubicin/daunomycin^1 | 7/85/12| 9/106/4| 8/80/2 | 10/64/2 |
| Cyclophosphamide^1     | 0.81/0.90 | 0.79/0.90 | 0.62/0.74 | 0.66/0.74 |
| Cranial irradiation    | 72     | 41     | Yes    |         |
| 6MP/MTX (weeks)        | 5/7/0  | 1/1/1  | 2*/0/1 | 0/0/1*  |
| Dead in CR1/relapse/SMN| 2.4 +/- 0.7% | 1.2 +/- 0.7% | 1.2 +/- 0.8% in total | 0.3 +/- 0.8% for non-transplanted |
| AML/MDS/solid tumor    |        |        |        |         |
| 12 year pSMN^2         |        |        |        |         |

AML = acute myeloid leukemia; CNS = central nervous system; Dead in CR1 = dead in first remission; M2/3 BM = ≥5%/25% leukemic blasts in bone-marrow; MDS=myelodysplastic syndrome; 6MP/MTX = duration of oral 6-mercaptopurine/methotrexate maintenance therapy in weeks; pEFS/pOS = the 12-year probability of event-free survival and overall survival, respectively; SR/IR/HR/VHR = standard/intermediate/high/very high risk acute lymphoblastic leukemia; WBC = white blood cell count; ^1Cumulative dose in mg/m^2; ^2The 12-year probability of developing a second malignant neoplasm; *Three of the four second malignant neoplasms (SMN) occurred after stem cell transplantation in 1st remission.

1:10^1-1:10^4 DNA nucleotides in leukocytes have been shown to be substituted with 6TGN (DNA-6TGN), but it is unknown, if the risk of t-AML/MDS is related to the individual leukocyte DNA-6TGN levels.

Conclusion: The relation between TPMT activity was not found in a recent large German BFM-study, but this may reflect both significant differences between that study and the present Nordic study with respect to the MTX/6MP dosages in the two protocols, and furthermore by the fact that only genotyping was used in the BFM study, whereas most patients in the Nordic study was classified by TPMT phenotyping. Thus, it remains to be explored whether TPMT genotyping or phenotyping is superior in predicting the risk of SMN. Since 2001, determination of TPMT geno-phenotype has been mandatory in NOPHO protocols, and during the initial maintenance therapy 6MP dose is reduced to 50 mg/m^2 for TPMT heterozygous patients. With longer follow-up it will be explored, if this approach has reduced the risk of SMN for such patients without compromising their low relapse rate.

To further increase the biological understanding of the development of SMN, an international study on SMN chaired by Maria Grazia Valsecchi (AIEOP) and Kjeld Schmiegelow (NOPHO) on behalf of the Ponte di Legno group has been initiated. This stuy will collect data on more than 700 SMNs occuring as the first event in children treated for ALL by 17 major childhood ALL groups in U.S., Europe and Asia.

Acknowledgement: This meeting review was written with support from The Danish Childhood Cancer Foundation; The Danish Cancer Society; the Home Secretary Research Grant for Individualised Therapy; and the Danish Research Council for Health and Disease. Kjeld Schmiegelow holds the Danish Childhood Cancer Foundation Research Professorship in Pediatric Oncology.

References:

1. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007 Mar 21;297(11):1207-15. doi:10.1001/jama.297.11.1207 PMid:17374815

2. Garwicz S, Anderson H, Olsen JH, Dollner H, Hertz H, Jomnundsson G, et al. Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 nordic countries. Int J Cancer 2000 Nov
Mediterr J Hematol Infect Dis 2011; 3: Open Journal System

15;88(4):672-8. doi:10.1002/1097-0213(20001115)88:4<672::AID-JHC24>3.0.CO;2-N

3. Bhatia S, SatherHN, PabustanOB, TriggME, GaynonPS, RobissonLL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukaemia after 1983. Blood 2002 Jun 15;99(12):4257-64. doi:10.1182/blood.V99.12.4257 PMid:1206851

4. Loning L, Zimmermann M, ReiterA, KaatschP, HenzeG, ReihtH, et al. Secondary neoplasms subsequent to BerlinFrankfurt-Münster therapy of acute lymphoblastic leukaemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000 May 1;95(9):2770-5. PMid:10779419

5. Ng A, TaylorGM, EdenOB. Treatment-related leukaemia - a clinical and scientific challenge. Cancer Treat Rev 2000 Oct;26(5):377-91. PMid:11061338

6. KampsWA, van der Paal-de Bruin KM, Veerman AJ, Paakko E, Harila M, Herva R, Tuominen J, Koivula KM, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009 Oct;11(5):530-12. doi:10.1093/neuonk/epp117 PMid:19714252 PMCID:2765343

7. Lando A, HolmK, Nyssom K, Krogh RA, Hoier MM, FeldtRasmussen U, et al. Serum thyroglobulin as a marker of thyroid neoplasms after childhood cancer. Acta Paediatr 2003 Nov;92(11):1284-90. PMid:14696488

8. Schmiegelow K, Renierse H, Hellebostad M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukaemia. Leukemia 2010 Feb;24(2):371-82. doi:10.1038/leu.2009.252 PMid:2010620 PMCID:2820159

9. Schmiegelow K, Forrestier E, Heyman M, Heyman M, Kristinsson J, Soderhall S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukaemia. Leukemia 2010 Feb;24(2):345-54. doi:10.1038/leu.2009.251 PMid:20106222

10. BanerjeeJ, PaakkoE, HarilaM, HervaR, TuominenJ, KoivulaK, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009 Oct;11(5):530-12. doi:10.1093/neuonk/epp117 PMid:19714252 PMCID:2765343

11. Stanulla M, Schaeffeler E, Moricke A, Coulthard SA, Cario G, Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukaemia. J Clin Oncol 2003 Apr 1;21(7):1332-9. doi:10.1200/JCO.2003.04.039 PMid:12663723

12. Schmiegelow K, Forrestier E, Kristinsson J, Soderhall S, Vettenranta K, Weinshilboum R, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukaemia - results from the NOPHO ALL-92 study. Leukemia. In press 2008.

13. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006 Mar;15(11):1629-38. doi:10.1038/sj.onc.1209372 PMid:16550163

14. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukaemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998;42(4):266-72. doi:10.1002/(SICI)1097-0142(1998)42:4<266::AID-CCP22>3.0.CO;2-5

15. Hedeland RL, Hvidt K, Nersting J, Rosthoj S, Dalhoff K, Lausen B, et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2010 Aug;66(3):485-91. doi:10.1007/s00280-009-1184-5 PMid:19956952

16. Relling MV, Boyett JM, Blanco JG, Raimondi SC, Behm FG, Sandlund JT, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003 May 15;101(10):3862-7. doi:10.1182/blood-2002-08-2405 PMid:12531808

17. Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Improving outcome through intensified methotrexate/6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999 Sep 15;86(6):1080-6. doi:10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-IJC24>3.0.CO;2-N

18. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Blanco JG, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995 Oct;9(10):1680-4. PMid:7564509

19. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999 Jul 3;354(9172):34-9. doi:10.1016/S0140-6736(99)81107-6

20. Relling MV, Yanishlevsy V, Nemec J, Evans WE, Boyett JM, Behm FG, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukaemia. Leukemia 1998 Mar;12(3):346-52. doi:10.1038/sj.leu.2400928 PMid:9529129

21. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 1997 Mar 4;36(9):2501-6. doi:10.1021/bi9621573 PMid:9054555

22. Swann PF, Waters TR, Mounton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996 Aug 23;273(5278):1109-11. doi:10.1126/science.273.5278.1109

23. Stanulla M, Schaeffeler E, Moricke A, Coullhard SA, Cario G, Schrauer A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukaemia on BerlinFrankfurt-Münster protocols. Blood 2009 Aug 15;114(7):1314-8. doi:10.1182/blood-2008-12-193250 PMid:19535798